Whittier Trust Co. Has $275,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Posted by Defense World Staff on Apr 8th, 2023

Whittier Trust Co. cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Rating) by 14.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 952 shares of the pharmaceutical company’s stock after selling 167 shares during the period. Whittier Trust Co.’s holdings in Vertex Pharmaceuticals were worth $275,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Old North State Trust LLC bought a new position in shares of Vertex Pharmaceuticals in the third quarter worth about $29,000. SJS Investment Consulting Inc. increased its stake in shares of Vertex Pharmaceuticals by 61.9% in the fourth quarter. SJS Investment Consulting Inc. now owns 102 shares of the pharmaceutical company’s stock worth $29,000 after purchasing an additional 39 shares during the period. American National Bank increased its stake in shares of Vertex Pharmaceuticals by 94.7% in the fourth quarter. American National Bank now owns 111 shares of the pharmaceutical company’s stock worth $32,000 after purchasing an additional 54 shares during the period. Ronald Blue Trust Inc. bought a new position in Vertex Pharmaceuticals during the second quarter valued at about $34,000. Finally, First Personal Financial Services bought a new position in Vertex Pharmaceuticals during the third quarter valued at about $36,000. 90.96% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Yuchun Lee sold 442 shares of the company’s stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $312.17, for a total transaction of $137,979.14. Following the completion of the sale, the director now owns 1,875 shares in the company, valued at approximately $585,318.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Vertex Pharmaceuticals news, Director Yuchun Lee sold 442 shares of the company’s stock in a transaction on Wednesday, January 18th. The shares were sold at an average price of $312.17, for a total transaction of $137,979.14. Following the completion of the sale, the director now owns 1,875 shares in the company, valued at approximately $585,318.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Reshma Kewalramani sold 10,000 shares of the company’s stock in a transaction on Wednesday, January 25th. The shares were sold at an average price of $315.05, for a total transaction of $3,150,500.00. Following the sale, the chief executive officer now owns 89,598 shares of the company’s stock, valued at approximately $28,227,849.90. The disclosure for this sale can be found here. In the last 90 days, insiders sold 47,952 shares of company stock worth $14,589,935. Insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Stock Down 0.1 %

NASDAQ:VRTX opened at $321.66 on Friday. The stock’s fifty day moving average price is $301.00 and its two-hundred day moving average price is $301.77. Vertex Pharmaceuticals Incorporated has a 52-week low of $233.01 and a 52-week high of $325.19. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.66 and a current ratio of 4.83. The company has a market cap of $82.70 billion, a price-to-earnings ratio of 25.07, a P/E/G ratio of 2.81 and a beta of 0.49.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Rating) last posted its quarterly earnings data on Tuesday, February 7th. The pharmaceutical company reported $3.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.11 by $0.65. Vertex Pharmaceuticals had a return on equity of 27.78% and a net margin of 37.20%. The firm had revenue of $2.30 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same quarter in the prior year, the business earned $3.18 EPS. The business’s revenue for the quarter was up 11.1% compared to the same quarter last year. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 12.36 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently issued reports on VRTX. HC Wainwright boosted their price target on Vertex Pharmaceuticals from $300.00 to $325.00 and gave the company a “buy” rating in a research note on Wednesday, February 8th. Morgan Stanley lowered their price target on Vertex Pharmaceuticals from $286.00 to $285.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 8th. SVB Leerink lowered their price target on Vertex Pharmaceuticals from $374.00 to $365.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 8th. Piper Sandler restated a “neutral” rating and set a $296.00 price target on shares of Vertex Pharmaceuticals in a research note on Wednesday, February 8th. Finally, Argus boosted their price target on Vertex Pharmaceuticals from $340.00 to $350.00 and gave the company a “buy” rating in a research note on Wednesday, March 29th. Six analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $327.30.

Vertex Pharmaceuticals Profile

(Get Rating)

Vertex Pharmaceuticals, Inc is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.